Limits...
A Decade of Experience Using mTor Inhibitors in Liver Transplantation.

Campsen J, Zimmerman MA, Mandell S, Kaplan M, Kam I - J Transplant (2011)

Bottom Line: We used mortality and graft loss as the primary measures of outcome.There were no significant differences in mortality or graft loss.There was no difference in patient or graft survival.

View Article: PubMed Central - PubMed

Affiliation: Division of Transplant Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USA.

ABSTRACT
Some studies suggest that Sirolimus (SRL) is associated with an increased risk of death in liver transplant recipients compared to treatment with calcineurin inhibitors (CNIs). We compared patients who received SRL or CNI in the first year after liver transplant. Our database included 688 patients who received a liver transplant. The patients were divided into groups. (1) CNI + MPS (mycophenolate sodium) at time of discharge. (2) CNI + MPS at time of discharge; SRL was added within the first 6 months and continued through the first year. (3) CNI + MPS at time of discharge; SRL was added within the first 6 months and discontinued before the first year. (4) SRL as primary immunosuppression. (5) SRL as primary immunosuppression and discontinued before the first year. We used mortality and graft loss as the primary measures of outcome. We also quantified renal function using the change in glomerular filtration rate (GFR), the presence of biopsy proven acute cellular reject (ACR), and steroid-resistant rejection (SRR). There were no significant differences in mortality or graft loss. There was no difference in patient or graft survival. Patients that received SRL as primary immunosuppression had 50% less rejection compared to controls.

No MeSH data available.


Related in: MedlinePlus

Graft survival by group. It depicts plots and tables of graft survival across the five groups represented by failure rates per 1000 person-months followup.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3064995&req=5

fig1: Graft survival by group. It depicts plots and tables of graft survival across the five groups represented by failure rates per 1000 person-months followup.

Mentions: Figure 1 depicts plots and tables of graft survival across the five groups represented by failure rates per 1000 person-months followup. There was no statistical difference in graft survival among the five groups of patients.


A Decade of Experience Using mTor Inhibitors in Liver Transplantation.

Campsen J, Zimmerman MA, Mandell S, Kaplan M, Kam I - J Transplant (2011)

Graft survival by group. It depicts plots and tables of graft survival across the five groups represented by failure rates per 1000 person-months followup.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3064995&req=5

fig1: Graft survival by group. It depicts plots and tables of graft survival across the five groups represented by failure rates per 1000 person-months followup.
Mentions: Figure 1 depicts plots and tables of graft survival across the five groups represented by failure rates per 1000 person-months followup. There was no statistical difference in graft survival among the five groups of patients.

Bottom Line: We used mortality and graft loss as the primary measures of outcome.There were no significant differences in mortality or graft loss.There was no difference in patient or graft survival.

View Article: PubMed Central - PubMed

Affiliation: Division of Transplant Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USA.

ABSTRACT
Some studies suggest that Sirolimus (SRL) is associated with an increased risk of death in liver transplant recipients compared to treatment with calcineurin inhibitors (CNIs). We compared patients who received SRL or CNI in the first year after liver transplant. Our database included 688 patients who received a liver transplant. The patients were divided into groups. (1) CNI + MPS (mycophenolate sodium) at time of discharge. (2) CNI + MPS at time of discharge; SRL was added within the first 6 months and continued through the first year. (3) CNI + MPS at time of discharge; SRL was added within the first 6 months and discontinued before the first year. (4) SRL as primary immunosuppression. (5) SRL as primary immunosuppression and discontinued before the first year. We used mortality and graft loss as the primary measures of outcome. We also quantified renal function using the change in glomerular filtration rate (GFR), the presence of biopsy proven acute cellular reject (ACR), and steroid-resistant rejection (SRR). There were no significant differences in mortality or graft loss. There was no difference in patient or graft survival. Patients that received SRL as primary immunosuppression had 50% less rejection compared to controls.

No MeSH data available.


Related in: MedlinePlus